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Abstract
Background and objective  Pemetrexed have been approved for the treatment of patients affected by advanced non-small cell 
lung cancner (NSCLC) in progression after first-line chemotherapy. We evaluated the activity and feasibility of pemetrexed in 
previously treated NSCLC. 
Methods  Patients with histologically or cytologically confirmed NSCLC were evaluated from April 2007 to March 2009. 
The patients had relapsed or progressed after prior chemotherapy treatment. Pemetrexed (500 mg/m
2) was administered 
intravenously once every 3 weeks after progression to prior chemotherapy. The tumor response was evaluated according to 
RECIST criteria by chest CT at every 2 cycles of chemotherapy.
Results  A total 61 patients were eligible for analysis. Performance status of them (100%) was over 2. The response rate and 
disease control rate were 14.7% and 37.7% respectively. Non-squamous cell carcinoma histology was significantly associated with 
a superior response rate (P=0.045) and disease control rate (P=0.008). The median survival time and the median progression 
free survival (PFS) time were 6.11 months and 2.17 months, respectively. Comparing the efficacy of pemetrexed in these two 
settings [second-line versus (12/61) more than third (49/61)], there was no significant difference in regard to median survival 
(11.18 months vs 11.46 months, P=0.922,5), but PFS was more longer in third- or further-line groups than second-line group 
(1.39 months vs 2.25 months, P=0.015,3). 
Conclusion  Pemetrexed is a feasible regimen in previously treated NSCLC with poor performance status.
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Introduction
Lung cancer is the leading cause of cancer-related 
deaths in Korea and worldwide[1,2]. More than 80% of 
patients with lung cancer have non-small cell lung cancer 
(NSCLC) histology[3]. Additionally, most NSCLC patients 
are diagnosed with locally advanced or metastatic disease. 
For advanced disease, systemic chemotherapy is the 
standard therapy. The standard first-line therapy for patients 
with NSCLC is platinum-based doublet combination 
chemotherapy, which offers a modest survival advantage[4]. 
As second-line chemotherapeutic agents, various drugs such 
as docetaxel, pemetrexed, and the epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib 
and gefitinib have been used. Among them, pemetrexed is a 
multi-target antifolate second-line chemotherapeutic agent[5] 
that shows effects comparable to docetaxel.
Presently, numerous NSCLC patients receive higher 
than third-line chemotherapy; however, a guideline for 
chemotherapy has not been established for these patients. 
Pemetrexed is less toxic than other therapeutics, and thus 
could be used safely in the elderly and in cases with poor 
Eastern Cooperative Oncology Group performance status 
(ECOG PS)[7,8]. Thus, pemetrexed could be used for later 
than third-line chemotherapy. However, until now, few 
studies have investigated the efficacy of pemetrexed in later 
than third-line chemotherapy with poor PS.
In the present study, the efficacy of pemetrexed in later 
than third-line chemotherapy in NSCLC patients with poor 
PS was examined retrospectively.
Patients and methods
Patients
The study population consisted of 56 patients who 
received pemetrexed because of progression after treatment 
at Chungnam National University Hospital between April 
2007 and March 2009. Clinicopathologic data and follow-up 
information were retrieved from patient medical records. All 
patients had histological or cytological confirmation of locally 
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advanced or metastatic NSCLC, stage IIIb or IV [tumor node 
metastasis (TNM) staging], and poor ECOG PS (≥2).
Treatment
All patients received 500 mg/m2 pemetrexed as a 10 min 
intravenous infusion on day 1 and every 21 days thereafter. 
Folic acid supplementation (1,000 mg) was orally administered 
daily beginning approximately 1-2 weeks before the first dose 
of pemetrexed and continued until 3 weeks after treatment 
discontinuation. A 1,000 mg vitamin B12 injection was 
administered intramuscularly approximately 1-2 weeks before 
the first dose of pemetrexed and was repeated approximately 
every 9 weeks until 3 weeks after therapy discontinuation. 
Dexamethasone was administered twice daily on the day before, 
the day of and the day after each dose of pemetrexed. Treatment 
was continued until disease progression, unacceptable toxicity, 
or the patient or physician decided to discontinue therapy.
Response
Tumor responses were assessed with computed tomography 
every two or three cycles to evaluate treatment responses for 
documentation of disease progression. Additionally, for cases 
with headache, nausea, vomiting, and other neurological 
symptoms (which together could indicate brain metastasis), 
systemic metastasis was evaluated by performing brain 
magnetic resonance imaging. For cases suspected to have bone 
metastasis, systemic metastasis was evaluated by bone scan or 
positron emission tomography-CT. Objective tumor responses 
were based on Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria[9].
Statistical analysis
Statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS) software (version 17.0; 
SPSS, Inc., Chicago, IL, USA). The survival period was from 
the day of the first administration of pemetrexed to death 
or the date that the follow-up observation was terminated. 
The progression-free survival (PFS) encompassed the time 
from the first cycle of pemetrexed therapy to documented 
progression or death from any cause until the date of the last 
follow-up visit for patients who were still alive and whose 
cancer had not progressed. For the analysis of survival period 
and PFS, the Kaplan-Meier method was used, and P-values 
were obtained based on the Log-rank test.  
For comparison of the characteristics of the patient 
groups, treatment response rate, and control of disease, the 
chi-square test was used. For analysis of factors mediating 
effects on survival, the Logistic regression model was used. 
Statistical significance was deemed to be P<0.05.
Results
Patient characteristics and distribution
Among 56 patients, 11 (19.6%) were treated with 
pemetrexed as second-line therapy, and 45 (80.4%) were 
administered pemetrexed as later than third-line therapy. 
The study group included 38 males (67.9%) and 18 females 
(32.1%). The age distribution was 43-81 years: 15 patients 
(26.8%) were >70 years, and 41 patients (73.2%) were 
<70 years. For patients >70 years, 63.6% were in second-
line treatment, whereas 17.8% were in later than third-line 
treatment. All 56 patients had an ECOG PS ≥2. In total, 32 
patients had non-squamous cell carcinoma (adenocarcinoma, 
n=29; indeterminate non-small-cell carcinoma, n=3), and 24 
(42.9%) patients had squamous cell carcinoma. Regarding 
disease stage, 16 patients exhibited less than stage IIIb, and 
40 exhibited stage IV disease. Almost all patients had been 
treated with a platinum-based chemotherapy as first-line 
treatment: 38 underwent a gemcitabine-platinum regimen, 
10 received a taxane-platinum regimen, and 5 were treated 
with an irinotecan-platinum regimen. The best response to 
first-line therapy was as follows: partial response (PR) in 25 
patients (44.6% of evaluable patients), stable disease (SD) 
in 15 patients (26.8%), and progressive disease (PD) in 16 
patients (28.6%) (Tab 1). 
Response
Among 56 cases, complete remission was achieved in 
one case (1.8%), partial remission was achieved in eight 
cases (14.3%), no change occurred in 14 cases (25.0%), and 
progressive lesions were found in 33 cases (58.9%). The 
treatment response rate was 16.1%, and the disease control 
rate was 41.1% (Tab 2). The median survival was 6.11 
months, and the median PFS was 2.17 months.
Subgroup analysis
The non-squamous cell cancer group included 18 cases 
(56.2%), and in comparison with the 5 cases in the squamous 
cell cancer group (20.8%), the disease control rate in the 
former group was significantly higher (P=0.018). Similarly, 
the treatment response rate for the non-squamous epithelial 
cancer group was 25.0% (8 cases), which was significantly 
higher than the 4.1% (1 case) for the squamous epithelial 
cancer group (P=0.045). By multivariate analysis, only 
histology showed persistent predictive relevance (Tab 3).
Efficacy of third- or further-line pemetrexed therapy
Pemetrexed was administered as part of second-line 
(19.6% of the patients), third-line (23.2% of the patients), 
fourth-line (35.7% of patients), and later than fifth-line 
chemotherapy (21.4% of the patients). In 80.4% of patients, 
pemetrexed was administered as later than third-line 
chemotherapy. When second-line was compared with 
later than third-line therapy, the median PFS was higher 
in later than third-line therapy (1.50 months vs 2.25 
months; P=0.017,1). The median survival of second-line 
chemotherapy was not significantly different from that in 
later than third-line chemotherapy (11.18 months vs 11.46 
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months; P=0.922,5).
Toxicity
The toxicity profiles of all patients are summarized in Tab 
4. Anemia was the most frequent adverse event (28.4%), 
followed by nausea (23%). Other adverse events were less 
frequent. Grade 3-4 hematologic toxicity occurred in 8.8% of 
cases. None of the patients required dose modifications due 
to toxicity.
Discussion 
Presently, first-line chemotherapy for progressive NSCLC 
consists of combination platinum-based chemotherapies[10]. 
For cases with disease recurrence or progressive disease 
after first-line therapy, docetaxel, pemetrexed, or an EGFR-
TKI (erlotinib or gefitinib) may be used. Among them, 
the median survival of docetaxel has been shown to be 
significantly longer than optimal palliative therapy, and thus 
Characteristic 2nd line [n (%)] 3rd or further line [n (%)] Total
All patients 11 (100%) 45 (100%) 56
Age (years)
     ≥70 7 (63.6%) 8 (17.8%) 15
      <70 4 (36.4%) 37 (82.2%) 41
Gender
      Male 8 (72.7%) 30 (66.7%) 38
      Female 3 (27.3%) 15 (33.3%) 18
ECOG PS
      2 7 (63.6%) 32 (71.1%) 39
      ≥3 4 (36.4%) 13 (28.9%) 17
Histology
      Adenocarcinoma 3 (27.3%) 26 (57.8%) 29
      Squamous cell carcinoma 6 (54.5%) 18 (40.0%) 24
      NSCLC 2 (18.2%) 1 (2.2%) 3
Stage
      ≤IIIb 3 (27.3%) 13 (28.9%) 16
      IV 8 (72.7%) 32 (71.1%) 40
First-line therapy
      Gemcitabine-platinum 6 (54.5%) 32 (71.2%) 38
      Taxane-platinum 1 (9.1%) 9 (20.0%) 10
      Irinotecan-platinum 3 (27.3%) 2 (4.4%) 5
      Others 1 (9.1%) 2 (4.4%)  3
Best response to first-line therapy
      PR-CR 4 (36.4%) 21 (46.7%) 25
      SD 2 (18.2%) 13 (28.9%) 15
      PD 5 (45.5%) 11 (24.4%) 16
Metastasis
      No metastasis 3 (27.3%) 13 (28.9%) 16
      Brain 1 (9.1%) 4 (8.9%) 5
      Bone 0 2 (4.4%) 2
      Adrenal gland 2 (18.2%) 4 (8.9%) 6
      Lung to lung 1 (9.1%) 10 (22.2%) 11
      Others 0 5 (11.1%) 5
      Multiple organs 4 (36.4%) 7 (15.6%) 11
Tab 1  Patients characteristics (n=56)
NSCLC: non-small cell lung cancer; PR: partial response; CR: complete response; SD: stable disease;  
PD: progressive disease.
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Best response 2nd line (n=11) 3rd line (n=13) 4th line (n=20) 5th line or further (n=12) Total (n=56)
Complete response 0 1 (7.7%) 0 0 1 (1.8%)
Partial response 0 3 (23.1%) 3 (15.0%) 2 (16.7%) 8 (14.3%)
Stable disease 3 (27.3%) 3 (23.1%) 6 (30.0%) 2 (16.7%) 14 (25.0%)
Progressive disease 8 (72.7%) 6 (46.2%) 11 (55.0%) 8 (66.7%) 33 (58.9%)
Disease control 3 (27.3%) 7 (53.8%) 9 (45.0%) 4 (33.3%) 23 (41.1%)
Tab 2  Best response data for each line pemetrexed therapy
Characteristic PFS (months) Univariate analysis Multivariate analysis
P Odds ratio (95%CI)
All patients 3.60
Age 0.187 0.315 (0.057-1.751)
      ≥70 years 3.10
      <70 years 3.79
Gender 0.300 2.111 (0.511-8.664)
      Male 3.12
      Female 4.62
Perfomance status 0.059 0.237 (0.053-1.058)
      2 4.21
      ≥3 2.22
Histology 0.018 0.178 (0.043-0.742)
      Non-squamous cell carcinoma 4.48
      Squamous cell carcinoma 2.44
Best response to first-line therapy 0.242 0.387 (0.79-1.899)
      Disease control (PR/SD) 4.02
      PD 2.58
No. of prior systemic therapy 0.904 0.897 (0.152-5.291)
      1 2.13
      ≥2 3.96
Tab 3  Univariate and multivariate analyses for progression-free survival
Grade 1 [n (%)] Grade 2 [n (%)] Grade 3 [n (%)] Grade 4 [n (%)]
Hematologic toxicity
      Neutropenia 0 2 (3.5%) 0 2 (3.5%)
      Anemia 6 (10.7%) 8 (14.2%) 2 (3.5%)
      Thrombocytopenia 1 (1.7%) 3 (5.3%) 0
Non-hematologic toxicity
      Nausea 0 8 (14.2%) 3 (5.3%) 2 (3.5%)
      Diarrhea 2 (3.5%) 2 (3.5%) 0
      Constipation 0 2 (3.5%) 0
      Rash 0 2 (3.5%) 1 (1.7%)
Tab 4  Toxicity profiles
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a survival benefit has been confirmed[11].
Compared with docetaxel, pemetrexed has demonstrated 
a similar median survival, and thus its efficacy is accepted. 
Importantly, its side effects were revealed to be safer than 
those from docetaxel[6,12]. 
In our study, pemetrexed was used as later than second-
line chemotherapy for NSCLC treatment. The treatment 
response rate was 16.1%, and the disease control rate was 
41.1%. The median survival was 6.11 months, and the median 
PFS was 2.17 months. Compared with the squamous cell 
cancer group, the non-squamous cell cancer group showed a 
statistically significantly higher treatment response rate and 
disease control rate. When second-line chemotherapy was 
compared with third-line or later chemotherapy, the median 
PFS of third-line or later chemotherapy was 2.25 months, 
which was statistically significantly longer than that with 
second-line therapy; however, the medial survival was not 
significantly different. A total of 11 patients were treated with 
pemetrexed as second-line therapy. Compared to 45 patients 
who received it as further-line therapy, the 11 patients who 
received second-line therapy were older and more frequently 
had squamous cell carcinoma (54.5% vs 40%). We believe 
that the longer PFS in the further-line pemetrexed group is 
explained by these differences in age and cancer type. In our 
study, only histology retained significance in the multivariate 
analysis. Grade 3-4 hematologic toxicity occurred in 8.8% of 
cases. Although the present study included a large proportion 
of elderly and poor PS patients, the toxicity profiles were mild 
and acceptable compared with the JMEI trial (a pemetrexed 
vs docetaxel trial)[6].
In a phase III clinical study examining the efficacy and safety 
of docetaxel and pemetrexed, prognostic factors included a PS 
of 0-1, stage III disease, and a relapse of >3 months after the last 
chemotherapy[6]. In the study conducted in Korea and reported 
by Lee et al[13], which assessed second-line chemotherapy 
for progressive NSCLC, pemetrexed monotherapy was 
administered for progressive NSCLC. The treatment response 
rate was 5.1%, and the disease control rate was 46.2%. The 
median survival was 7.8 months, and the median PFS was 3.1 
months. Factors mediating the effects on the treatment response 
rate were not determined, and independent factors mediating 
the effects on the disease control rate were non-smoker status 
and adenocarcinoma cancer type.
In another study reported by Lee et al[14], examining cases 
that used pemetrexed as second-line or later chemotherapy, 
the treatment response rate was 11%, and the disease control 
rate was 66%. The median survival was 13 months, and 
the median PFS was 2.3 months. In comparison with the 
squamous epithelial cancer group, the treatment response 
and disease control rates of the non-squamous epithelial 
cancer group were shown to be significantly higher, which 
was similar to our study.
In the study reported by Sun et al[15], the patients receiving 
pemetrexed were divided into two groups: the second-line 
group and the third-line or later group. The percentages in 
these two groups were 30% and 70%, respectively, which is 
comparable to our study, in which the ratio of third-line or later 
pemetrexed patients was 80.4%. The treatment response rate 
was 12%, and the disease control rate was 55%. The median 
survival in that study was 12.8 months, and the median PFS 
was 3.03 months. When the PFS for second-line chemotherapy 
was compared with that for with third-line chemotherapy, 
no significant difference was detected. The only independent 
factor that showed a survival benefit was PS.
Longer median PFS was found in the study reported by 
Lee, Sun, et al[14,15] and this was thought to be related to the 
fact that 79% and 59% of subjects were in PS levels 0 and 
1, respectively, whereas in our study, 100% of cases were 
at PS levels 2 and higher. Thus, in the studies described 
above, as well as in our study, for NSCLC patients with poor 
PS, particularly for those with non-squamous cell cancer, 
pemetrexed is effective as second-line or later chemotherapy. 
In cases when it is used as later than third-line chemotherapy, 
its efficacy was comparable to that for second-line therapy, 
and as in our study, for cases whose ECOG PS is >2, it was 
found to be efficacious.
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